GlassScriptPhysician profile
Shazia Hamid
NPI 1811955214
$2,766.08
in general payments reported to CMS, 2019-2025
22 companies · $490 in 2025
The $490 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $203 · 2021: $362 · 2022: $500 · 2023: $286 · 2024: $754 · 2025: $490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,529.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,529.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $488.14 | 2019-2025 | Airsupra, Farxiga |
| Amgen INC. | $405.27 | 2019-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $351.51 | 2022-2025 | Rybelsus, Ozempic |
| Almatica Pharma LLC | $211.09 | 2024-2025 | Loreev Xr, Teriparatide |
| Idorsia Pharmaceuticals US INC | $193.65 | 2022-2024 | Quviviq |
| Genentech USA, INC. | $159.83 | 2020-2022 | |
| Pfizer INC. | $127.94 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $127.37 | 2022-2025 | Zoryve |
| Lilly USA, LLC | $120.62 | 2023-2024 | Mounjaro, Zepbound |
| Mylan Specialty L.P. | $108.70 | 2019-2021 | |
| Abbvie INC. | $108.25 | 2022-2024 | |
| Dexcom, INC. | $86.36 | 2021-2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $66.33 | 2021-2024 | Freestyle Libre 3 |
| Astellas Pharma US INC | $55.96 | 2024-2025 | Veozah |
| Aytu Biopharma, INC. | $29.91 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $22.42 | 2019 | |
| Medtronic, INC. | $20.77 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $19.14 | 2025 | Austedo Xr |
| Eisai INC. | $18.45 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.81 | 2025 | |
| Halozyme INC | $14.55 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shazia Hamid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.